During the corresponding time, Sensus Healthcare Inc saw a revenue deteriorated by -66.83 % year on year, sequentially revenue fell by -32.53 %. While revenue at the Sensus Healthcare Inc 's corporate clients
Sensus Healthcare Inc's Comment on Sales, Marketing and Customers
Sensus Healthcare, Inc. operates in the United States and China, with a significant portion of sales concentrated with one U.S. customer. The company provides non-invasive treatments for non-melanoma skin cancer and post-surgical keloid scar prevention using proprietary low-energy X-ray technology known as superficial radiation therapy (SRT). Its product line includes the SRT-100, SRT-100+, and SRT-100 Vision treatment devices. In February 2024, Sensus established a wholly owned subsidiary, Sensus Healthcare Services, LLC, which delivers operational healthcare services to dermatology clinics. These services include equipment provision, radiation oncology and physicist oversight, and on-site device operation by radiotherapy technologists under a service model termed the "Fair Deal Agreement."
In a groundbreaking move for veterinary medicine, Tel Aviv s largest veterinary emergency hospital has acquired Sensus Healthcare s SRT-100, a state-of-the-art radiotherapy device traditionally used to treat cancer in humans. This marks the first veterinary commercial sale of the SRT-100 outside the United States, revolutionizing the way tumors in cats and dogs are treated. Offering a gentler and more effective approach, this acquisition promises to provide our beloved furry companions with cutting-edge cancer care.The SRT-100: A Milestone for Veterinary Oncology:The SRT-100, developed by Sensus Healthcare, deploys a highly targeted form of radiation therapy called superficial radiation therapy (SRT). Unlike...
Sensus Healthcare Inc’s Comment on Sales, Marketing and Customers
Sensus Healthcare, Inc. operates in the United States and China, with a significant portion of sales concentrated with one U.S. customer. The company provides non-invasive treatments for non-melanoma skin cancer and post-surgical keloid scar prevention using proprietary low-energy X-ray technology known as superficial radiation therapy (SRT). Its product line includes the SRT-100, SRT-100+, and SRT-100 Vision treatment devices. In February 2024, Sensus established a wholly owned subsidiary, Sensus Healthcare Services, LLC, which delivers operational healthcare services to dermatology clinics. These services include equipment provision, radiation oncology and physicist oversight, and on-site device operation by radiotherapy technologists under a service model termed the "Fair Deal Agreement."
Sources:
Sensus Healthcare Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Sensus Healthcare Inc’s corporate clients.
For your research, we’ve provided 9 tables on Sensus Healthcare Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
126.38 %